Tempest Therapeutics TPST
NASDAQ TPST
$0.40 +0.02 (+6.09%)
At close: Nov 11, 2026 · 4:00 PM EST

Tempest Therapeutics (TPST) Gains from Sales and Divestitures (2018 - 2021)

Updated

Tempest Therapeutics (TPST) reported Gains from Sales and Divestitures of -$9,000 for Q1 2021.

Analysis

Tempest Therapeutics (TPST) Gains from Sales and Divestitures (2018 - 2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Tempest Therapeutics 5.91 Mn -11.91 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2021 -9,000.00
Sep 30, 2018 32,000.00
API Access

Tempest Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=TPST&period=max&api_key=YOUR_API_KEY